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Background: The high frequencies of recurrence and distant metastasis of adenoid cystic carcinoma (AdCC)
emphasize the need to better understand the biological factors associated with these outcomes. To analyze the
mechanisms of AdCC metastasis, we established the green fluorescence protein (GFP)-transfected subline ACCS-GFP
from the AdCC parental cell line and the metastatic ACCS-M GFP line from an in vivo metastasis model.
Methods: Using these cell lines, we investigated the involvement of the epithelial–mesenchymal transition (EMT)
and cancer stem cell (CSCs) in AdCC metastasis by real-time RT-PCR for EMT related genes and stem cell markers.
Characteristics of CSCs were also analyzed by sphere-forming ability and tumorigenicity. Short hairpin RNA (shRNA)
silencing of target gene was also performed.
Results: ACCS-M GFP demonstrated characteristics of EMT and additionally displayed sphere-forming ability and
high expression of EMT-related genes (Snail, Twist1, Twist2, Slug, zinc finger E-box binding homeobox 1 and 2
[Zeb1 and Zeb2], glycogen synthase kinase 3 beta [Gsk3β and transforming growth factor beta 2 [Tgf-β2]), stem cell
markers (Nodal, Lefty, Oct-4, Pax6, Rex1, and Nanog), and differentiation markers (sex determining region Y [Sox2],
Brachyury, and alpha fetoprotein [Afp]). These observations suggest that ACCS-M GFP shows the characteristics of
CSCs and CSCs may be involved in the EMT of AdCC. Surprisingly, shRNA silencing of the T-box transcription factor
Brachyury (also a differentiation marker) resulted in downregulation of the EMT and stem cell markers. In addition,
sphere-forming ability, EMT characteristics, and tumorigenicity were simultaneously lost. Brachyury expression in
clinical samples of AdCC was extremely high and closely related to EMT. This finding suggests that regulation of
EMT by Brachyury in clinical AdCC may parallel that observed in vitro in this study.
Conclusions: The use of a single cell line is a limitation of this study. However, parallel data from in vitro and
clinical samples suggest the possibility that EMT is directly linked to CSCs and that Brachyury is a regulator of EMT
and CSCs.
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Adenoid cystic carcinoma (AdCC) is one of the most
common malignant tumors of the salivary glands and is
characterized by unique clinical features and behavior.
AdCC grows slowly but spreads relentlessly into adja-
cent tissues. The frequencies of recurrence and distant
metastasis of AdCC are very high, with 40–60% of
AdCC patients developing distant metastases to the
lungs, bone, and soft tissues [1,2]. Therefore, distant fail-
ure remains a significant obstacle to the long-term cure
of patients with AdCC, emphasizing the need to better
understand the biological factors associated with AdCC
distant metastases.
To identify the factors that mediate AdCC metastasis,
we established 3 AdCC cell lines expressing green fluor-
escent protein (GFP) from the ACCS cell line by using
orthotopic transplantation and in vivo selection in the
nude mouse: the parental ACCS-GFP, the highly
tumorigenic ACCS-T GFP, and the metastatic ACCS-M
GFP. These cells were subjected to DNA microarray
analysis, and the results revealed significantly altered
biological processes in ACC-M GFP, including events
related to cell adhesion and signaling. In particular, a
significant downregulation of cell adhesion molecules
such as E-cadherin and integrin subunits was observed.
We confirmed the loss of E-cadherin and integrins and
gain of vimentin in ACCS-M GFP, suggesting that the
epithelial–mesenchymal transition (EMT) is a putative
event in AdCC metastasis and induces tumor cell dis-
semination from the primary tumor site [3].
Recent evidence has demonstrated that the EMT is
involved in a dedifferentiation program in epithelial
tumor progression. This process interrupts cell-to-cell
contact in a homocellular fashion in tumors and allows
the dissemination of a single cell from the primary site.
Therefore, EMT may be one of the important pheno-
typic alterations promoting nonmetastatic tumor transi-
tion to metastatic carcinoma [4,5].
The EMT program triggered during tumor progres-
sion appears to be controlled by genes normally
expressed in the early embryo, including Twist, Snail,
Slug, Goosecoid, and Sip1 [6-11]. The transcription fac-
tors encoded by these genes can impart the traits of
mesenchymal cells to tumor cells, including motility
and invasiveness. The expression of Twist, for example,
is elevated in various types of cancers including breast,
prostate, gastric, and melanoma [12]. In addition, the
T-box transcription factor Brachyury, a gene required for
mesoderm formation during the development process
[13-15], is also reportedly able to promote the EMT
in human carcinoma cell lines [16]. The latter study
additionally revealed that overexpression of Brachyury
(also described as a mesoderm differentiation marker) in
human carcinoma cells induced changes characteristic ofEMT. Therefore, mechanisms similar to EMT in human
developmental processes are proposed to control EMT in
cancer cells.
Independent of these studies, neoplastic tissue studies
have provided evidence of self-renewing, stem-like cells
within tumors, termed cancer stem cells (CSCs). CSCs
constitute a minority of neoplastic cells within a tumor
and are defined operationally by their ability to seed new
tumors. For this reason, they have also been called
“tumor-initiating cells” [17]. During the process of tumor
metastasis, which is often enabled by EMT [18], dissemi-
nated cancer cells presumably require a self-renewal
capability similar to that exhibited by stem cells in order
to spawn macroscopic metastases. This phenomenon
raises the possibility that the EMT process, which enables
cancer cell dissemination, may also impart a self-renewal
capability to disseminating cancer cells. Indeed, emerging
evidence of a direct interaction between EMT and CSCs
has been recently reported [16,19-22]. CSCs were shown
to be resistant to chemotherapy and radiotherapy [21,23]
and these studies therefore provide a new concept for
therapies that target CSCs [24-28].
Given these reports and our previous results, we
hypothesized that the EMT in our AdCC metastasis
model involves AdCC stem cells and that the devel-
opment of anti-CSC therapy may be effective in the
treatment of AdCC. In this study, we demonstrate evi-
dence of a direct interaction between the EMT and
CSCs in the highly metastatic AdCC subclone ACCS-M
GFP. We also report that the T-box transcription factor
Brachyury [29-31] is a possible central regulator of
CSCs and the EMT in AdCC cells.
Results
AdCC cells with EMT characteristics also have CSC-like
phenotypes
We previously isolated the highly metastatic and tumori-
genic AdCC subline ACCS-M GFP from nonmetastatic
(0% incidence) and low tumorigenic (22.2% incidence)
parental ACCS GFP cells using in vivo selection as
described in the Methods [3]. ACCS-M GFP exhibited
high tumorigenicity (100% incidence), high frequency of
spontaneous metastasis to submandibular lymph nodes
(100% incidence), and significant characteristic changes
of the EMT, such as loss of E-cadherin and gain of
vimentin [3]. Ample evidence has accumulated indicat-
ing that the EMT is closely correlated with CSCs. AdCC
cells with the EMT phenotype (ACCS-M GFP) also
showed significant tumorigenicity, which is an important
phenotype of CSCs [3]. Therefore, we assessed the
stemness of ACCS cell lines with the sphere-forming
assay. The parental ACCS GFP cells demonstrated
weak sphere-forming capacity in diameter and number,
whereas ACCS-M GFP cells showed significant sphere-
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ACCS-M GFP was approximately twice the diameter
of ACCS GFP in the primary and secondary spheres
(Figure 1B). Furthermore, the number of spheres was
more significantly different in the secondary spheres
than in the primary spheres. The number of spheres of
ACCS-M GFP was approximately 10 times higher than
that of ACCS GFP (Figure 1C). These data suggest that
ACCS-M GFP cells have self-renewal (sphere-forming)
ability.
AdCC cells with EMT characteristics express EMT-related
genes and stem-cell markers
We next quantified the expression levels of possible
CSC markers by real-time RT-PCR, which are shown
as relative mRNA levels compared to β-actin mRNA
(Table 1). ACCS cells expressed higher levels of genes
such as Snail, Slug, Tgf-β2, Pax6, and Brachyury than
other genes tested. Expression levels of EMT-related
genes such as Snail, Twist1, Twist2, Slug, zinc finger
E-box binding homeobox 1 and 2 (Zeb1 and Zeb2),
glycogen synthase kinase 3 beta (Gsk3β and transform-
ing growth factor beta 2 (Tgf-β2) were elevated from
2-fold to 9-fold in ACCS-M GFP compared to ACCSFigure 1 Cells with EMT alterations show sphere-forming ability. ACC
mL in serum-free medium containing 40 ng/mL bFGF and 20 ng/mL EGF f
spheres, primary spheres (day 10) were dissociated into single cells and fur
observed under a phase contrast microscope (A). Sphere diameters were m
Sphere numbers were standardized as sphere number/104 cells originally c
triplicate, and the values were averaged. Bars indicate the standard deviatio
**P< 0.01.GFP (Figure 2A). This increased expression in ACCS-M
GFP was especially apparent with Slug (approximately
4-fold), Zeb1 (approximately 9-fold), and Zeb2 (approxi-
mately 5.5-fold). Stem cell markers (Nodal, Lefty, Oct-4,
Pax6, Rex1, and Nanog) and differentiation markers
(sex determining region Y [Sox2], Brachyury, and Afp)
were also overexpressed in ACCS-M GFP, with the ex-
ception Oct-4 and Nanog (Figure 2B). Together, these
data suggest that ACCS-M GFP cells have CSC-like
phenotypes and are related to the EMT.
Knockdown of the T-box transcription factor Brachyury
downregulates EMT-related genes and stem-cell markers
We next sought direct evidence of linkage between
EMT and CSCs with the aim to simultaneously reveal
the central regulator(s) of CSC stemness. Several of the
CSC markers in Figure 2 are transcription factors, and
recent reports have demonstrated that the T-box tran-
scription factor Brachyury promotes the EMT in human
tumor cells [16,32]. Therefore, we focused on the possi-
bility that Brachyury regulates not only EMT but also
CSC stemness. We also focused on SOX2, which has
also been reported as one of the key element genes for
embryonic or pluripotent stem cells. We used a stableS-GFP and ACCS-M GFP cells were cultured at a density of 5 × 104 cells/
or floating culture for 10 days (primary spheres). For secondary
ther cultured at a density of 1 × 104 cells/mL for 10 days. Spheres were
easured (B), and spheres with a diameter >100 μm were counted.
ultured (C) in each sphere period. Experiments were performed in
n. Data significance was analyzed by Student’s t-test. *P< 0.05,
Table 1 Analysis of gene expression levels related to EMT
and CSCs by real-time PCR
Genes Cell
line
Relative mRNA level (normalized to β-actin)
Mean expression levels SD
Snail ACCS 2.02 × 10-2 4.18 × 10-3
ACCSM 5.14 × 10-2 2.62 × 10-3
Slug ACCS 1.05 × 10-2 4.82 × 10-3
ACCSM 4.14 × 10-2 2.92 × 10-3
Twist1 ACCS 1.47 × 10-4 5.24 × 10-5
ACCSM 3.37 × 10-4 1.12 × 10-5
Twist2 ACCS 4.68 × 10-3 2.67 × 10-4
ACCSM 8.04 × 10-3 1.38 × 10-4
Zeb1 ACCS 3.21 × 10-3 5.13 × 10-4
ACCSM 2.92 × 10-2 6.16 × 10-4
Zeb2 ACCS 1.40 × 10-3 6.23 × 10-4
ACCSM 7.39 × 10-3 4.12 × 10-4
Tgf-β2 ACCS 5.43 × 10-2 3.56 × 10-2
ACCSM 1.81 × 10-1 7.52 × 10-2
Gsk3β ACCS 3.39 × 10-3 1.82 × 10-4
ACCSM 8.73 × 10-3 6.43 × 10-4
Nodal ACCS 3.72 × 10-3 4.36 × 10-4
ACCSM 7.14 × 10-3 2.15 × 10-4
Pax 6 ACCS 6.34 × 10-2 4.26 × 10-2
ACCSM 1.10 × 10-1 8.21 × 10-2
Rex 1 ACCS 1.12 × 10-3 2.42 × 10-4
ACCSM 2.45 × 10-3 2.93 × 10-4
Lefty ACCS 3.39 × 10-3 1.51 × 10-4
ACCSM 9.88 × 10-3 7.12 × 10-4
Brachyury ACCS 1.55 × 10-2 5.32 × 10-3
ACCSM 2.83 × 10-2 6.24 × 10-3
Sox 2 ACCS 9.35 × 10-3 2.12 × 10-4
ACCSM 1.94 × 10-2 8.92 × 10-4
AFP ACCS 9.50 × 10-3 3.52 × 10-4
ACCSM 1.83 × 10-2 9.96 × 10-4
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pin RNA (shRNA) in lentiviral plasmids. Following
Brachyury and SOX2 knockdown, the expression levels
of all examined CSC markers were assessed by real-time
RT-PCR (Figure 3). Each mRNA level was compared
with ACCS GFP, and data are shown as relative mRNA
levels (ACCS GFP= 1). The expression levels of EMT-
related genes (Figure 3A) and stem cell markers and dif-
ferentiation markers (Figure 3B) are shown. The mRNA
levels of all CSC markers decreased in Brachyury-
knockdown ACCS-M GFP cells (ACCS-M shBra) com-
pared to ACCS GFP. In contrast, SOX2-knockdown
ACCS-M GFP cells (ACCS-M shSOX2) demonstratedspecific downregulation of only Snail, Zeb1, Zeb2, Tgfβ2,
Rex1, Nanog, and Afp mRNA. Importantly, SOX2
knockdown failed to regulate Brachyury mRNA expres-
sion. These results strongly suggest that Brachyury is a
central regulator of CSC and EMT.
Knockdown of the T-box transcription factor Brachyury
negates EMT phenotypes
We then confirmed the EMT phenotype in ACCS-M shBra
and ACCS-M shSOX2. The protein level of β-catenin
was increased and shifted to higher molecular weight in
ACCS-M GFP. The protein level of β-catenin was
decreased in ACCS-M shBra and ACCS-M shSOX2
cells, reaching similar levels to that observed in ACCS
GFP; however, the molecular weight of β-catenin was
increased, similar to ACCS-M GFP.
The protein level of E-cadherin was increased in
ACCS-M shBra and recovered to the approximate level
observed in ACCS GFP cells, but recovery in ACCS-M
shSOX2 was incomplete (Figure 4). Vimentin protein
level was decreased in both ACCS-M shBra and ACCS-M
shSOX2 cells compared to ACCS-M GFP, reaching similar
levels to that observed in ACCS GFP.
Knockdown of the T-box transcription factor Brachyury
inhibits sphere-forming capacity
We examined the self-renewal capability of ACCS-M
shBra and ACCS-M shSOX2 by sphere-forming assay.
Similar to ACCS GFP cells, ACCS-M shBra and ACCS-M
shSOX2 lost sphere-forming capacity with respect to
the diameter of the primary (Figure 5A) and secondary
spheres (Figure 5B) and with respect to the number of
cells in the primary spheres (Figure 5C). Furthermore,
the number of spheres was more significantly lower in
the secondary spheres than in the primary spheres, and
ACCS-M shBra significantly reduced sphere number in
comparison to ACCS-M shSOX2 (Figure 5D). These
data suggest that Brachyury is a more important regula-
tor of EMT and CSC than SOX2.
Knockdown of the T-box transcription factor Brachyury
inhibits tumorigenicity and metastasis in vivo
The effect of Brachyury knockdown on ACCS-M GFP
tumorigenicity and metastasis in vivo was examined
using a mouse metastasis model established and
reported by Ishii et al. [3]. Figure 6A shows a typical
tumor in tongue (a–c), its GFP excitation (d–f ), and
submandibular lymph node metastasis (g–i). Remark-
ably, ACCS-M shBra sometimes failed to develop into
tongue tumor (50% tumorigenicity), and metastasis was
completely inhibited. ACCS-M shSOX2 also reduced
tumorigenicity (87.5%) and metastasis (87.5%), but the
impact of inhibition was more relevant with ACCS-M
Figure 2 Analysis of gene expression related to EMT and CSCs by real-time PCR. The mRNA expression levels of the indicated EMT-related
genes (A) and embryonic stem cell markers (Nodal, Pax6, Rex1, Lefty, Oct-4, and Nanog) and differentiation markers (mesoderm marker:
Brachyury; ectoderm marker: Sox2; endoderm marker: AFP) (B) in ACC cells were quantified by real-time RT-PCR. Each mRNA level was compared
between ACCS GFP and ACCS-M GFP, and data are shown as relative mRNA levels to β-actin mRNA. Experiments were performed in triplicate,
and the number of adhered cells was averaged. Bars indicate the standard deviation.
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cantly inhibited in ACCS-M shBra cells (Figure 6B).
Expression and molecular localization of Brachyury and
EMT markers in oral AdCC lesions
We examined the expression and expression pattern
of Brachyury in oral AdCC lesions using immunohis-
tochemistry. Figure 7A shows the representative stain-
ing pattern of Brachyury on AdCC (a: tubular pattern.
b: cribriform pattern, c: solid pattern). Brachyury was
localized to the cytoplasm and/or nucleus of AdCC
cells. We examined 21 AdCC samples, and all samples
demonstrated positive expression of Brachyury in AdCC
cells (positive expression rate =100%, Table 3). To find
evidence that Brachyury was associated with EMT,
we analyzed localization of Brachyury (Figure. 7B-b),
E-cadherin (Figure. 7B-c), and vimentin (Figure. 7B-d)
in AdCC tissue by immunofluorescence staining ofserial sections. The lateral layer of the AdCC cells
expressed Brachyury in the nucleus (Figure. 7B-b,
arrowheads). These cells lost expression of E-cadherin
(Figure. 7B-c, arrowheads) and gained expression of
vimentin (Figure. 7B-d, arrowheads).
Discussion
Cancer metastasis is the most crucial event directly in-
fluencing patient prognosis. Recent studies suggest that
the EMT is strongly correlated with cancer invasion
and metastasis [33,34]. In contrast, CSCs have gained
attention as targets for cancer treatment because they
show chemo- and radioresistance [21,35-37]. More re-
cently, EMT was reported to promote the CSC signa-
ture [19,38-40]; however, the regulatory mechanism of
CSC and EMT is still unclear.
We demonstrated a direct correlation between EMT
and CSCs in AdCC cells. Importantly, the EMT we
Figure 3 Effect of Brachyury shRNA on ACCS-M GFP gene expression related to EMT and CSCs. ACCS-M-sh. control was generated by the
transfection of ACCS-M GFP cells with control vector. ACCS-M sh Brachyury and ACCS-M sh Sox2 were generated by the transfection of ACCS-M
GFP cells with Brachyury shRNA and Sox2 shRNA, respectively. The mRNA expression levels of the indicated genes in ACCS-M GFP cells and
derivatives were quantified by real-time RT-PCR. Each mRNA level was compared with ACCS GFP, and data are shown as relative mRNA levels
(ACCS GFP= 1). The expression levels of EMT-related genes (A) and stem cell markers and differentiation markers (B) are shown. Experiments
were performed in triplicate, and the number of adhered cells was averaged. Bars indicate the standard deviation.
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model and was not artificially isolated [33], exogenous
[41,42], or genetically promoted [43], as described previ-
ously. Therefore, the findings that we report here
strongly support the hypothesis that CSCs are involved
in the EMT. This study is the first to identify Brachyury
as a regulator for both EMT and CSC characteristics.
This conclusion is based on the observation that Brachy-
ury knockdown resulted in simultaneous loss of all stem
cell markers and loss of EMT and CSC phenotypes in
morphological and biochemical assays.The classification of EMT into 3 subtypes based on
the biological and biomarker context in which they
occur has been proposed [44,45]. EMT associated with
organ development is referred to as type 1 EMT, and
EMT associated with wound healing and tissue regener-
ation are type 2 EMT. EMT in cancer progression and
metastasis is categorized as type 3 EMT. Multiple extra-
cellular signals including TGF-β, receptor tyrosine
kinases, Notch, nuclear factor kappa B (NFκB), and Wnt
can initiate the type 3 EMT program. The downstream
intracellular signaling pathways and transcription factors
Figure 4 Silencing of Brachyury recovers the epithelial signature of ACCS-M GFP cells. sh control (sh. con) cells were generated by the
transfection of ACCS GFP or ACCS-M GFP cells with control vector. sh Brachyury (sh.Bra) or sh SOX2 (sh.SOX2) cells were generated by the
transfection of ACCS GFP or ACCS-M GFP cells with Brachyury shRNA or SOX2 shRNA. Cells were cultured for 24 h on culture dishes, and cell
lysates were prepared and resolved using 10% SDS-PAGE. The levels of EMT-related biomarkers were detected by immunoblotting with
antibodies against the indicated proteins. All experiments were performed at least in triplicate, and representative results are shown.
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nificant crosstalk, including multiple positive feedback
loops [46,47].
This principle of EMT suggests that the phenomenon
may be reversible if such extracellular signals are
removed. However, our established cell line, ACCS-M
GFP, is stable and does not change to a nonmetastatic
phenotype after several passages. Recent data from
mammary epithelial cells also demonstrate that continu-
ous activation of the EMT leads to epigenetic alterationsFigure 5 Brachyury silencing reduces the sphere-forming ability of AC
shRNAs (−, untreated control; con, control shRNA; Bra, Brachyury shRNA; Sox2
as described in the legend for Figure 1. Sphere diameters were measured (A)
were standardized as sphere number/104 cells originally cultured (B) in each s
were averaged. Bars indicate the standard deviation. Data significance was anin cells that induce heritable effects to maintain the
EMT state even after EMT-inducing signals or factors
are no longer present [48]. Hence, under certain condi-
tions such as in vivo selection, EMT can yield stable
changes in phenotype and thus the lineage identity of
cells. In these cells, all possible pathways initiating EMT
are constitutively active without any stimulation, as
shown in Figure 3. This characteristic may make the
cells self-renewing, the most important phenotype of
CSCs. This type of phenotypic alteration or cell selectionCS-M GFP cells. ACCS cells and ACCS derivatives transfected with
, SOX2 shRNA) were cultured, and sphere-forming ability was quantified
, and spheres with a diameter >100 μm were counted. Sphere numbers
phere period. Experiments were performed in triplicate, and the values
alyzed by Student’s t-test. *P<0.05, **P<0.01.
Figure 6 Brachyury silencing reduces the tumorigenicity and metastasis of ACCS-M GFP cells. A. ACCS-M GFP derivatives transfected with
shRNAs (untreated control, ACCS-M GFP [a, d, g]; Brachyury shRNA, M sh.Bra [b, e, h]; SOX2 shRNA, M sh.SOX2 [c, f, i]) were injected into the
tongues of nude mice and examined to detect tumors in tongues (a–f) and spontaneous metastases in submandibular lymph nodes (g–i).
Observations with the naked eye (a–c) and the excitation of GFP (d–i) are shown. Sites of lymph node metastasis are labeled with arrowheads.
Note that GFP enables the detection of micro-metastasis in the lymph nodes. B. The primary tumor volumes were measured weekly, calculated
as the length ×width × thickness, and mice were sacrificed when the primary tumor volume reached 100 mm3. Tumor growth curves for ACCS
derivatives ACCS-M GFP (diamond), sh.Bra (square), sh.SOX2 (triangle), and sh cont. (control shRNA, circle) are shown. Experiments were
performed in 6 mice for each ACCS derivative, and the values were averaged. Bars indicate the standard deviation. Data significances between
ACCS-M GFP and other ACCS derivatives were analyzed by Student’s t-test. *P<0.05, **P< 0.01.
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radiotherapy for cancer treatment in vivo.
Although much is known about the mechanisms or
signals involved in type 1 and type 2 EMT [49,50], type
3 EMT-specific signaling still remains to be resolved in
epithelial carcinoma cells. Our study indicates that one
such possibility is the constitutive upregulation of TGF-β2in ACCS-M GFP cells. TGF-β appears to be responsible
for the induction or functional activation of a series of
EMT-inducing transcription factors in cancer cells,
notably Snail, Slug, ZEB1, Twist, Goosecoid, and
FOXC2 [51-53]. Constitutive upregulation of TGF-β2
would therefore maintain the EMT or CSC status in an
autocrine manner.
Table 2 Tumorigenicity and metastasis of each cell line
Tumorigenicity Metastasis
Cell line Tumorigenic mouse (%) Tumor volume (mm3) *SMLN (%) LUNG (%)
ACCS-M GFP 8/8 (100) 145.3 8/8 (100) 7/8 (87.5 )
ACCS-M sh cont. 8/8 (100) 121.4 8/8 (100) 7/8 (87.5%)
ACCS-M sh Br. 4/8 (50) 28.3 N.D N.D
ACCS-M sh SOX2 7/8 (87.5) 37.2 7/8 (87.5) 3/8 (37.5%)
N.D: not detected
*Submandibular lymph nodes.
Figure 7 Immunohistochemical analysis of Brachyury, E-cadherin, and vimentin in AdCC tissue. Sections of 4-μm thickness were used for
the histopathological and immunohistochemical analysis as described in the Methods. A. Representative staining pattern of Brachyury on AdCC
(a: tubular pattern, b: cribriform pattern, c: solid pattern). Bar = 50 μm. B. Serial AdCC sections were stained with HE (a) or immunostained with
Brachyury (b), E-cadherin (c), and vimentin (d). Bar = 50 μm.
Shimoda et al. BMC Cancer 2012, 12:377 Page 9 of 15
http://www.biomedcentral.com/1471-2407/12/377












1 M 56 Sublingual gland Cribriform - - + +
2 F 83 Sublingual gland Cribriform - - + +
3 F 71 Sublingual gland Solid - Lung + +
4 M 70 Sublingual gland Cribriform - - + +
5 M 34 Palate Tubular - - + +
6 F 25 Palate Cribriform - - + +
7 F 64 Upper gingiva Tubular - Lung bone + +
8 F 58 Palate Solid + - + +
9 F 76 Sublingual gland Solid + - + +
10 F 75 Sublingual gland Cribriform + - + -
11 M 58 Palate Cribriform + - + +
12 F 80 Sublingual gland Cribriform - - + +
13 M 61 Lower gingiva Solid - Lung brain + +
14 F 57 Upper gingiva Cribriform - Lung bone + +
15 M 63 Palate Solid + Liver + +
16 F 59 Palate Tubular - - + +
17 F 65 Sublingual gland Cribriform - - + +
18 M 65 Upper gingiva Solid - - + +
19 F 70 Sublingual gland Solid + Lung + +
20 M 69 Palate Cribriform - - + +
21 F 48 Upper gingiva Cribriform - Lung + +
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http://www.biomedcentral.com/1471-2407/12/377Brachyury is a T-box transcription factor with an evo-
lutionarily conserved function in vertebrate develop-
ment, whereby it is required for mesoderm formation
[13-15]. Brachyury is also highly expressed in various
human epithelial tumors and human tumor cell lines
(lung, colon, and prostate carcinomas), but not in
human normal adult tissues [32]. However, no studies
have analyzed the role of Brachyury in tumor cells.
Recently, Fernando et al. [16] reported that Brachyury
promotes EMT in human carcinoma cell lines. Their
study demonstrated that overexpression of Brachyury in
human carcinoma cells induced EMT, including upregu-
lation of mesenchymal markers, downregulation of epi-
thelial markers, and increase in cell migration and
invasion.
Downregulation of E-cadherin transcription is induced
by Brachyury overexpression and partially mediated by
Slug. In our model, Brachyury was overexpressed in the
ACCS-M GFP (EMT cell line), and the expression level
was 2-fold greater than that of the parental cell line. In
contrast, overexpression of ZEB1 and ZEB2 in the EMT
cell line was 5- and 9-fold higher, respectively, compared
to parental cells. Surprisingly, Brachyury silencing by
shRNA in ACCS-M GFP cells resulted in an almost
complete inhibition of EMT-related genes and stem cellmarkers, including ZEB1 and ZEB2. This significant
change induced by Brachyury silencing promoted the
mesenchymal to epithelial transition (gain of E-cadherin
and loss of vimentin) and loss of the CSC phenotype
(sphere formation and tumorigenicity).
The mechanisms of Brachyury regulation of the EMT
and stem cell-related genes are not certain. Brachyury
and other members of the T-box transcription family
preferentially bind to the palindromic consensus element
AATTTCACACCTAGGTGTGAAATT, and a half-site
(TCACACCT) of this consensus sequence is located at
position −645 of the human E-cadherin promoter. Bra-
chyury is able to bind to the E-cadherin promoter
in vitro, although with low efficiency [16]. Other reports
have suggested low-affinity binding of T-box proteins
to a half consensus site, such as the one present in the
E-cadherin promoter [54,55]. However, the in vivo
binding of Brachyury to the half-site on the E-cadherin
promoter could be greatly improved by interactions
with accessory proteins or cofactors. Brachyury overex-
pression in tumor cells induces a concurrent enhance-
ment of Slug expression, followed by the effective
silencing of E-cadherin transcription as a result of
Brachyury and Slug association within the E-cadherin
promoter region [16].
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shown to control desmosomal disruption during the ini-
tial and necessary steps of EMT in addition to repressing
E-cadherin transcription [56,57]. Induction of EMT by
FGF-1 treatment or Slug overexpression in the rat
bladder carcinoma cell line NBT-II is also character-
ized by dissociation of desmosomes, with no change in
E-cadherin expression [57]. Therefore, Slug may mainly
control desmosomal proteins such as plakoglobin dur-
ing the initial step of EMT and associate with Brachyury
to regulate E-cadherin and accomplish EMT.
During the developmental process in vertebrates,
Brachyury regulates downstream genes that are compo-
nents of signaling pathways such as noncanonical Wnt/
planar cell polarity (Wnt/PCP), NFκB, and TGF-β sig-
naling [58]. Sox2 (SRY Sex Determining Region Y-Box2)
is a member of the Sox (SRY-related HMG box) family
of transcription factors. Sox2 regulates expression of
multiple genes, especially stable expression of Oct-3/4,
which is also a transcription factor that maintains stem-
ness and pluripotency in normal stem cells. Recently, an
association between SOX2 and EMT was also reported.
Activation of SOX2 induces TGF-β downstream signal-
ing including activation of Wnt, Notch, and Hedgehog
signals, followed by induction of Snail mRNA expres-
sion to ultimately result in inhibition of E-cadherin
transcription through induction of ZEB1/2 expression.
This phenomenon is consistent with our mRNA expres-
sion results after SOX2 knockdown. Importantly, unlike
Brachyury knockdown, SOX2 knockdown only inhib-
ited genes downstream of TGF-β and failed to inhibit
Brachyury expression. In contrast, Brachyury knock-
down inhibited almost all the genes tested including
Sox2 and its downstream genes. Also of note, silencing
of SOX2 inhibited EMT but not tumorigenicity and me-
tastasis. Therefore, it is possible that Brachyury controls
multiple functional signals related to EMT and CSC
simultaneously. The impact of the simultaneous silen-
cing effect of Brachyury on EMT and CSC phenotypes
observed in this study support this hypothesis. Add-
itionally, these data suggest the existence of a partial
but direct link between the EMT and CSC and that Bra-
chyury is one of the central regulators of EMT and CSC
maintenance in AdCC cells.
The use of a single cell line is a limitation of this study.
It is quite difficult to establish CSC-like cell lines in vitro
and this is an obstacle to research in this field. However,
parallel data from clinical samples support our hypothesis
in part. Brachyury expression in clinical AdCC samples
was extremely high (positive expression rate = 100%), and
the data suggested a close relationship with EMT (loss of
E-cadherin and gain of vimentin). Therefore, at least the
regulation mechanism of EMT by Brachyury demon-
strated in this study may also occur in clinical AdCC.From a clinical perspective, CSC-targeted therapy
should have strict selectivity for CSCs, which is a serious
obstacle for most molecular targeted therapies presently
used. Selective expression of Brachyury has been
reported in various human tumors of epithelial origin,
but not in most human normal adult tissues [32], a fact
that strongly encourages the use of this molecule as a
clinical therapeutic target.
Conclusions
We conclude that the EMT is directly linked to CSC,
and Brachyury is one of the central regulators of the
EMT and CSC in our single cell line study. These results
suggest that Brachyury is a potential therapeutic target
for future anti-CSC treatments of AdCC.
Methods
Cells and culture
The human cell lines ACCS, ACCS GFP, and ACCS-M
GFP were established in our laboratory as described
previously [3]. In brief, the parental cell line ACCS and
green fluorescence protein (GFP)-transfected subline
ACCS-GFP displayed similar morphologies, growth rates,
and tumorigenicity both in vitro and in vivo. Similar to the
parental ACCS, the tumorigenicity of ACCS-GFP cells
was low (22.2% incidence). Using ACCS-GFP cells,
tumor formation in the tongues of nude mice injected
with tumor cells was clearly observed under excitation
light, while green fluorescence was not observed in the
absence of tumors. We performed in vivo selection of
clones with higher tumorigenicity by repeatedly reco-
vering cells in vitro and transplanting them into the ton-
gues of nude mice. Consequently, a subline exhibiting
high tumorigenicity (100% incidence) and high fre-
quency of spontaneous metastasis to submandibular
lymph nodes (100% incidence), ACCS-M GFP, was
obtained through this in vivo selection process. The
histological and immunohistochemical features of
ACCS-M GFP tumors were similar to the solid pattern
of AdCC. The cell lines were maintained as a monolayer
culture in Dulbecco's modified Eagle's medium (DMEM;
Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% fetal bovine serum (ICN Biomedicals, Aurora, OH,
USA), 2 mML-glutamine, penicillin G, and strepto-
mycin in a humidified incubator with an atmosphere of
5% CO2 at 37°C.
Immunoblot analysis
To visualize cell adhesion molecules and their related
proteins, cells were rinsed with phosphate-buffered
saline (PBS) and lysed in ice-cold buffer (50 mM Tris–
HCl [pH 7.5], 150 mM NaCl, 2 mM ethylene glycol
tetraacetic acid [EGTA], and 1% Triton X-100) contain-
ing protease inhibitor cocktail (Sigma-Aldrich). The
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was quantified using a protein assay kit (Bio-Rad La-
boratories, Hercules, CA, USA). Equal amounts of pro-
tein from each sample were resuspended in sodium
dodecyl sulfate (SDS) sample buffer (10% SDS, 62.5 mM
Tris–HCl [pH 6.8], and 50% glycerol). Before electro-
phoresis, reduced samples were adjusted to 5% (v/v) 2-
mercaptoethanol and boiled for 5 min. The samples
were separated on 10% SDS–polyacrylamide gels and
transferred electrophoretically onto nitrocellulose mem-
branes (Bio-Rad Laboratories). After blocking with 5%
skim milk in Tris-buffered saline containing 0.1%
Tween-20, the membranes were incubated overnight
with primary antibodies at 4°C, followed by horseradish
peroxidase-conjugated secondary antibodies (DAKO,
Carpinteria, CA, USA) for 1 h. The bound antibodies
were visualized using ECL immunoblotting detection
reagents (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). The following primary antibodies were used
for immunoblotting: mouse monoclonal anti-vimentin
(V9) purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); mouse monoclonal anti-E-cadherin
purchased from BD Transduction Laboratories (Frank-
lin Lakes, NJ, USA); rabbit polyclonal anti-β-catenin
purchased from Upstate (Temecula, CA, USA); and
mouse monoclonal anti-β-actin (A5316) purchased
from Sigma-Aldrich.
Real-time RT-PCR
The mRNA expression levels of the indicated EMT-
related genes, embryonic stem cell markers (Nodal,
Pax6, Rex1, Lefty, Oct-4, and Nanog), and differentiation
markers (mesoderm marker, Brachyury; ectoderm mar-
ker, Sox2; endoderm marker, AFP) in ACC cells were
quantified by real-time RT-PCR.
Total RNA was extracted from ACCS cells using TRI-
zol (Invitrogen, Carlsbad, CA, USA) and used for first-
strand cDNA synthesis. The mRNA levels were quanti-
fied in triplicate using a real-time PCR system with the
Brilliant SYBR Green qPCR Kit (Stratagene, La Jolla,
CA, USA). The specific primers for EMT, stem cells,
and differentiation markers were as follows: hSnail (F)
50-TCCACAAGCACCAAGAGTC-30, (R) 50-ATGGCAG




(F) 50-AGGAGCTCGAGAGGCAG-30, (R) 50-CGTTGA
GCGACTGGGTG-30; hZEB1 (F) 50-CTCACACTCTGG
GTCTTATTCTC-30, (R) 50-GTCTTCATCCTCTTCCC
TTGTC-30; hZEB2 (F) 50-AAAGGAGAAAGTACCAGC
GG-30, (R) 50-AGGAGTCGGAGTCTGTCATATC-30; hT
GF-β (F) 50-TTAACATCTCCAACCCAGCG-30, (R) 50-
TCCTGTCTTTATGGTGAAGCC-30; hGSK3β (F) 50-GGTCTATCTTAATCTGGTGCTGG-30, (R) 50-AGGTT
CTGCGGTTTAATATCCC-30; hNodal (F) 50-ACCCAG
CTGTGTGTACTCAA-30, (R) 50-TGGTAACGTTTCAG
CAGAC-30; hOct-4 (F) 50-TATCGAGAACCGAGTGA-
GAG-30, (R) 50-TCGTTGTGCATAGTCGCT-30; hPax6
(F) 50-GGCGGAGTTATGTATACCTAC-30, (R) 50-CTT
GGCCAGTATTGAGACAT-30; hRex1 (F) 50-AAACGG
GCAAAGACAAGA-30; (R) 50-GCTCATAGCACACAT
AGCCAT-30; hLefty (F) 50-TGTATCCATTGAGCCCT
CT-30, (R) 50-CAGGAAATGGAAGGACACA-30; hNa-
nog (F) 50-ACCCAGCTGTGTGTACTCAA-30, (R) 50-G
CGTCACCATTGCTATT-30; hBrachyury (F) 50-TGCT
GCAATCCCATGACA-30, (R) 50-CGTTGCTCACAGAC
CACA-30; hSOX2 (F) 50-TGGGTTCGGTGGTCAAGT-30,
(R) 50-CTCTGGTAGTGCTGGGACA-30; hAFP (F) 50-
CTGCAAACTGACCACGCT-30, (R) 50-TGAGACAG
CAAGCTGAGGAT-30.
The PCR cycling conditions consisted of 10 min at 95°
C for 1 cycle followed by 45 cycles at 95°C for 30 s, 60°C
for 30 s, and 72°C for 60 s. Dissociation curve analyses
confirmed that the signals corresponded to unique
amplicons. Expression levels were normalized to β-actin
mRNA levels for each sample obtained from parallel
assays and analyzed using the LightCyclerW2.0 System
software package (Roche Applied Science, Indianapolis,
IN, USA).
Sphere-forming assay
ACCS cells were seeded at a density of 5 × 104 cells/mL
in 60-mm noncoated dishes with serum-free DMEM
containing 40 ng/mL basic fibroblast growth factor
(bFGF) and 20 ng/mL epidermal growth factor (EGF)
for floating cultures. The cells were cultured in a hu-
midified incubator in an atmosphere of 5% CO2 at 37°C,
and bFGF and EGF were added to the medium every
other day. After 10 days, the diameters of developed cell
clusters were measured, and cell clusters with a diam-
eter >100 μm were counted as spheres. For passaging,
primary spheres (day 10) were treated with 0.05% tryp-
sin/0.02% EDTA and dissociated into single cells, after
which the cells were added to 24-well culture plates at a
density of 1 × 104 cells/mL in serum-free medium. The
cells were cultured for a further 10 days in serum-free
medium to obtain secondary spheres.
Transfection of Brachyury and SOX2 shRNA
Cultured ACCS cells were transfected with shRNA
lentiviral plasmids (pLKO.1-puro; Sigma-Aldrich) using
Lipofectamine LTX (Invitrogen) according to the manu-
facturer’s instructions. ACCS-sh. control and ACCS-M-sh.
control cells were generated by the transfection of ACCS
GFP and ACCS-M GFP cells with pLKO.1-puro Control
Vector (Sigma-Aldrich), respectively. ACCS-shBra and
ACCS-M-shBra cells were generated by the transfection
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puro/sh. Brachyury (Sigma-Aldrich), respectively. Simi-
larly, ACCS-shSOX2 and ACCS-M-shSOX2 cells were
generated by the transfection of ACCS GFP and ACCS-
M GFP cells with pLKO.1-puro/sh. SOX2 (Sigma-
Aldrich), respectively. Colonies exhibiting resistance to
puromycin (Sigma-Aldrich) were pooled from the indi-
vidual transfection experiments. The expression level of
Brachyury in shRNA-transfected ACCS cells was moni-
tored by real-time RT-PCR. All transfected cells were
maintained in DMEM containing 10% fetal bovine
serum and 2 μg/mL puromycin (Sigma-Aldrich).
ACCS metastatic orthotopic implantation mouse model
The animal experimental protocols were approved by
the Animal Care and Use Committee of Kyushu Uni-
versity. Eight-week-old female athymic nude mice
(BALBcAJcl-nu) were purchased from Kyudo (Fukuoka,
Japan). The mice were housed in laminar flow cabinets
under specific pathogen-free conditions in facilities
approved by Kyushu University. For the experimental
metastasis studies, 1 × 106 cells in 40 μL phosphate-
buffered saline (PBS) were injected into the tongue
using a syringe with a 27-gauge disposable needle
(TOP Plastic Syringe, Tokyo, Japan) under intraperito-
neal diethyl ether anesthesia. The primary tumor
volumes were measured weekly, calculated as length ×
width × thickness, and mice were sacrificed when the
primary tumor volume reached 100 mm3. After sacri-
fice, tumors of the tongue and metastases, from tongue
tumor in cervical lymph nodes, lungs, and liver were
visualized macroscopically under light excitation. After
visualization, the primary tumors and metastatic sites were
examined pathologically and immunohistochemically.
Immunohistochemistry
All biopsies were obtained from 21 patients who had
been diagnosed with primary AdCC and treated at the
Department of Oral and Maxillofacial Surgery, Kyushu
University Hospital, Fukuoka, Japan, between 1993 and
2006. The protocol for this research project has been
approved by a suitably constituted Ethics Committee of
Kyushu University. The biopsy samples were fixed in
10% neutralized buffered formalin. Consecutive 4-μm-
thick sections were cut, deparaffinized with xylene, and
rehydrated in a graded alcohol series, followed by heat
treatment with Target Retrieval Solution (Dako, Carpin-
teria, CA, USA), and then used for the histopathological
and immunohistochemical analyses.
To block endogenous peroxide activity, 3% H2O2
was applied, and nonspecific reactions were blocked
with 10% normal blocking serum in Tris–HCl buffer.
The sections were incubated overnight at 4°C with the
following primary antibodies: rabbit polyclonal anti-human Brachyury (H-210; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), mouse monoclonal anti-human
E-cadherin (610181; BD Bioscience, California, CA,
USA), and goat polyclonal anti-human vimentin (C-20;
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunostaining was performed with the Histofine
SAB-PO kit (Nichirei, Tokyo, Japan), in accordance
with the manufacturer’s instructions. The immunolo-
calization of the protein was visualized using DAB
substrate kit (Nichirei). The sections were counter-
stained with 0.5% hematoxylin, dehydrated, cleared,
and mounted. Negative control staining consisted of
substituting non-immune goat serum for the primary
antibodies.
Statistical analysis
All data were displayed as mean ± SD, analyzed via ana-
lysis of variance and Student’s t-test, and processed by
the statistical software SPSS 13.0. Statistical significance
was assumed at P < 0.05.
Competing interests
The authors have no potential conflicts of interest to disclose.
Authors’ contributions
TS conceived of the study, participated in its design and coordination,
performed experiments, analyzed data, performed statistical analysis, and
drafted the manuscript. MS performed experiments, analyzed data,
performed statistical analysis, and drafted the manuscript. II performed
immunohistochemical staining. KI analyzed data and helped in drafting the
manuscript. SC contributed materials and helped in drafting the manuscript.
YK performed experiments, analyzed data, and performed statistical analysis.
KS conceived of the study and participated in its design and coordination.
All authors read and approved the final manuscript.
Acknowledgments
This work was supported by Grants-in-Aid (No. 23390465) from the Ministry
of Education, Culture, Sports, Science, and Technology of Japan (to T. S).
Received: 4 June 2012 Accepted: 20 August 2012
Published: 29 August 2012
References
1. Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA,
Douzinas EE, Patsouris E: Adenoid cystic carcinoma of the head and neck.
Clinicopathological analysis of 23 patients and review of the literature.
Oral Oncol 2005, 41:328–335.
2. Ampil FL, Misra RP: Factors influencing survival of patients with adenoid
cystic carcinoma of the salivary glands. J Oral Maxillofac Surg 1987,
45:1005–1010.
3. Ishii K, Shimoda M, Sugiura T, Seki K, Takahashi M, Abe M, Matsuki R, Inoue
Y, Shirasuna K: Involvement of epithelial-mesenchymal transition in
adenoid cystic carcinoma metastasis. Int J Oncol 2011, 38:921–931.
4. Tarin D, Thompson EW, Newgreen DF: The fallacy of epithelial
mesenchymal transition in neoplasia. Cancer Res 2005, 65:5996–6000.
discussion 6000–599.
5. Thompson EW, Newgreen DF, Tarin D: Carcinoma invasion and metastasis:
a role for epithelial-mesenchymal transition? Cancer Res 2005, 65:
5991–5995. discussion 5995.
6. Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular
mechanisms contribute to epithelial plasticity and metastasis. Nat Rev
Mol Cell Biol 2003, 4:657–665.
7. Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat
Rev Mol Cell Biol 2002, 3:155–166.
Shimoda et al. BMC Cancer 2012, 12:377 Page 14 of 15
http://www.biomedcentral.com/1471-2407/12/3778. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A: The
transcription factor Slug represses E-cadherin expression and induces
epithelial to mesenchymal transitions: a comparison with Snail and E47
repressors. J Cell Sci 2003, 116:499–511.
9. Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-
mesenchymal transition during tumor progression. Curr Opin Cell Biol
2005, 17:548–558.
10. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner
P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of
morphogenesis, plays an essential role in tumor metastasis. Cell 2004,
117:927–939.
11. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG,
Portillo F, Nieto MA: The transcription factor snail controls epithelial-
mesenchymal transitions by repressing E-cadherin expression. Nat Cell
Biol 2000, 2:76–83.
12. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao
SY, Tzeng CH, Tai SK, et al: Bmi1 is essential in Twist1-induced epithelial-
mesenchymal transition. Nat Cell Biol 2010, 12:982–992.
13. Kispert A, Herrmann BG, Leptin M, Reuter R: Homologs of the mouse Brachyury
gene are involved in the specification of posterior terminal structures in
Drosophila, Tribolium, and Locusta. Genes Dev 1994, 8:2137–2150.
14. Behr R, Heneweer C, Viebahn C, Denker HW, Thie M: Epithelial-mesenchymal
transition in colonies of rhesus monkey embryonic stem cells: a model for
processes involved in gastrulation. Stem Cells 2005, 23:805–816.
15. Vidricaire G, Jardine K, McBurney MW: Expression of the Brachyury gene
during mesoderm development in differentiating embryonal carcinoma
cell cultures. Development 1994, 120:115–122.
16. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C: The T-
box transcription factor Brachyury promotes epithelial-mesenchymal
transition in human tumor cells. J Clin Invest 2010, 120:533–544.
17. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer
stem cells. Nature 2001, 414:105–111.
18. Thiery JP: Epithelial-mesenchymal transitions in development and
pathologies. Curr Opin Cell Biol 2003, 15:740–746.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal
transition generates cells with properties of stem cells. Cell 2008,
133:704–715.
20. Berry NB, Bapat SA: Ovarian cancer plasticity and epigenomics in the
acquisition of a stem-like phenotype. J Ovarian Res 2008, 1:8.
21. Ahmed N, Abubaker K, Findlay J, Quinn M: Epithelial mesenchymal
transition and cancer stem cell-like phenotypes facilitate
chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets
2010, 10:268–278.
22. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA,
Neve RM, Lenburg ME, Thompson EW: Epithelial mesenchymal transition
traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-)
stem cell phenotype in human breast cancer. J Mammary Gland Biol
Neoplasia 2010, 15:235–252.
23. Alison MR, Lim SM, Nicholson LJ: Cancer stem cells: problems for therapy?
J Pathol 2011, 223:147–161.
24. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH: Targeting
miRNAs involved in cancer stem cell and EMT regulation: An emerging
concept in overcoming drug resistance. Drug Resist Updat 2010,
13:109–118.
25. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B,
Menendez JA: Metformin regulates breast cancer stem cell ontogeny by
transcriptional regulation of the epithelial-mesenchymal transition (EMT)
status. Cell Cycle 2010, 9:3807–3814.
26. Sarkar FH, Li Y, Wang Z, Kong D: NF-kappaB signaling pathway and its
therapeutic implications in human diseases. Int Rev Immunol 2008,
27:293–319.
27. Raimondi C, Gianni W, Cortesi E, Gazzaniga P: Cancer stem cells and
epithelial-mesenchymal transition: revisiting minimal residual disease.
Curr Cancer Drug Targets 2010, 10:496–508.
28. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS:
AACR special conference on epithelial-mesenchymal transition and
cancer progression and treatment. Cancer Res 2010, 70:7360–7364.
29. Herrmann BG, Labeit S, Poustka A, King TR, Lehrach H: Cloning of the T
gene required in mesoderm formation in the mouse. Nature 1990,
343:617–622.30. Kispert A, Hermann BG: The Brachyury gene encodes a novel DNA
binding protein. EMBO J 1993, 12:4898–4899.
31. Edwards YH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA, Sowden J:
The human homolog T of the mouse T(Brachyury) gene; gene structure,
cDNA sequence, and assignment to chromosome 6q27. Genome Res
1996, 6:226–233.
32. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL,
Baranova AV, Kozlov AP, Schlom J: The human T-box mesodermal
transcription factor Brachyury is a candidate target for T-cell-mediated
cancer immunotherapy. Clin Cancer Res 2007, 13:2471–2478.
33. Creighton CJ, Chang JC, Rosen JM: Epithelial-mesenchymal transition
(EMT) in tumor-initiating cells and its clinical implications in breast
cancer. J Mammary Gland Biol Neoplasia 2010, 15:253–260.
34. Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB:
Epithelial-to-mesenchymal transition of murine liver tumor cells
promotes invasion. Hepatology 2010, 52:945–953.
35. Sarkar FH, Li Y, Wang Z, Kong D: Pancreatic cancer stem cells and EMT in
drug resistance and metastasis. Minerva Chir 2009, 64:489–500.
36. Monteiro J, Fodde R: Cancer stemness and metastasis: therapeutic
consequences and perspectives. Eur J Cancer 2010, 46:1198–1203.
37. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an
emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741–4751.
38. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C:
A novel lung metastasis signature links Wnt signaling with cancer cell
self-renewal and epithelial-mesenchymal transition in basal-like breast
cancer. Cancer Res 2009, 69:5364–5373.
39. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell
and epithelial-mesenchymal transition markers are frequently
overexpressed in circulating tumor cells of metastatic breast cancer
patients. Breast Cancer Res 2009, 11:R46.
40. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH: Epithelial to
mesenchymal transition is mechanistically linked with stem cell
signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
41. Wendt MK, Allington TM, Schiemann WP: Mechanisms of the epithelial-
mesenchymal transition by TGF-beta. Future Oncol 2009, 5:1145–1168.
42. Kabashima A, Higuchi H, Takaishi H, Matsuzaki Y, Suzuki S, Izumiya M, Iizuka
H, Sakai G, Hozawa S, Azuma T, Hibi T: Side population of pancreatic
cancer cells predominates in TGF-beta-mediated epithelial to
mesenchymal transition and invasion. Int J Cancer 2009, 124:2771–2779.
43. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S,
Srour EF, Nakshatri H: SLUG/SNAI2 and tumor necrosis factor generate
breast cells with CD44+/CD24- phenotype. BMC Cancer 2010, 10:411.
44. Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like
cells. J Clin Invest 2009, 119:1417–1419.
45. Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal
transitions. J Clin Invest 2009, 119:1429–1437.
46. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131–142.
47. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour
progression: an alliance against the epithelial phenotype? Nat Rev Cancer
2007, 7:415–428.
48. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD:
Sustained induction of epithelial to mesenchymal transition activates
DNA methylation of genes silenced in basal-like breast cancers. Proc Natl
Acad Sci USA 2008, 105:14867–14872.
49. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J
Clin Invest 2009, 119:1420–1428.
50. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-
mesenchymal transitions: the importance of changing cell state in
development and disease. J Clin Invest 2009, 119:1438–1449.
51. Fuxe J, Vincent T, Garcia de Herreros A: Transcriptional crosstalk between
TGFbeta and stem cell pathways in tumor cell invasion: Role of EMT
promoting Smad complexes. Cell Cycle 2010, 9:2363–2374.
52. Lindley LE, Briegel KJ: Molecular characterization of TGFbeta-induced
epithelial-mesenchymal transition in normal finite lifespan human
mammary epithelial cells. Biochem Biophys Res Commun 2010, 399:659–664.
53. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K,
Onder TT, Gupta PB, Evans KW, et al: Core epithelial-to-mesenchymal
transition interactome gene-expression signature is associated with
claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci
USA 2010, 107:15449–15454.
Shimoda et al. BMC Cancer 2012, 12:377 Page 15 of 15
http://www.biomedcentral.com/1471-2407/12/37754. Muller CW, Herrmann BG: Crystallographic structure of the T domain-DNA
complex of the Brachyury transcription factor. Nature 1997, 389:884–888.
55. Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR: Tbx3 represses
E-cadherin expression and enhances melanoma invasiveness. Cancer Res
2008, 68:7872–7881.
56. Savagner P, Kusewitt DF, Carver EA, Magnino F, Choi C, Gridley T, Hudson
LG: Developmental transcription factor slug is required for effective re-
epithelialization by adult keratinocytes. J Cell Physiol 2005, 202:858–866.
57. Savagner P, Yamada KM, Thiery JP: The zinc-finger protein slug causes
desmosome dissociation, an initial and necessary step for growth factor-
induced epithelial-mesenchymal transition. J Cell Biol 1997,
137:1403–1419.
58. Hotta K, Takahashi H, Satoh N, Gojobori T: Brachyury-downstream gene
sets in a chordate, Ciona intestinalis: integrating notochord specification,
morphogenesis and chordate evolution. Evol Dev 2008, 10:37–51.
doi:10.1186/1471-2407-12-377
Cite this article as: Shimoda et al.: The T-box transcription factor
Brachyury regulates epithelial–mesenchymal transition in association
with cancer stem-like cells in adenoid cystic carcinoma cells. BMC Cancer
2012 12:377.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
